Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3917904 | 0.71 | GAA (0.34) | — | |
| SCHEMBL5568649 | 0.68 | CES1 (0.37) | CES1PARP1LMNAPKM | |
| SCHEMBL23339779 | 0.66 | CES1 (0.41) | CES1PARP1LMNAPKM | |
| SCHEMBL4611133 | 0.65 | CA9 (0.50) | PKM | |
| SCHEMBL8344705 | 0.65 | CA2 (0.38) | PARP1LMNA | |
| SCHEMBL11481318 | 0.62 | DRD1 (0.36) | LMNA | |
| SCHEMBL1278375 | 0.61 | BCL2L1 (0.52) | CES1PARP1 | |
| SCHEMBL3919989 | 0.60 | MEN1 (0.42) | LMNAPKM | |
| SCHEMBL11477363 | 0.60 | CA2 (0.33) | — | |
| SCHEMBL3079019 | 0.60 | BCL2L1 (0.39) | CES1PARP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534787-B2 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-7393843-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BORNEMANN KLAUS | 2008-06-12 | — | — | US | disclosed |
| US-7375220-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | CES1 69/4885PARP1 2488/4885LMNA 35/4885 |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | APP, BACE1, PSEN1 | CES1 69/4885PARP1 2488/4885LMNA 35/4885 |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | CES1 69/4885PARP1 2488/4885LMNA 35/4885 |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | CES1 73/4885PARP1 2502/4885LMNA 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.